Scandion Oncology (Sweden) Probability of Future Stock Price Finishing Over 0.0725
| SCOL Stock | SEK 0.07 0 3.97% |
Scandion |
Scandion Oncology Target Price Odds to finish over 0.0725
The tendency of Scandion Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.07 | 90 days | 0.07 | about 98.0 |
Based on a normal probability distribution, the odds of Scandion Oncology to move above the current price in 90 days from now is about 98.0 (This Scandion Oncology AS probability density function shows the probability of Scandion Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Scandion Oncology AS has a beta of -0.41. This usually implies as returns on the benchmark increase, returns on holding Scandion Oncology are expected to decrease at a much lower rate. During a bear market, however, Scandion Oncology AS is likely to outperform the market. Additionally Scandion Oncology AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Scandion Oncology Price Density |
| Price |
Predictive Modules for Scandion Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Scandion Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Scandion Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Scandion Oncology is not an exception. The market had few large corrections towards the Scandion Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Scandion Oncology AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Scandion Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.02 | |
β | Beta against Dow Jones | -0.41 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | -0.23 |
Scandion Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Scandion Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Scandion Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Scandion Oncology generated a negative expected return over the last 90 days | |
| Scandion Oncology has high historical volatility and very poor performance | |
| Scandion Oncology has some characteristics of a very speculative penny stock | |
| Scandion Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (51.7 M) with loss before overhead, payroll, taxes, and interest of (32.32 M). | |
| Scandion Oncology AS has accumulated about 131.54 M in cash with (49.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Scandion Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Scandion Stock often depends not only on the future outlook of the current and potential Scandion Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Scandion Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.6 M | |
| Cash And Short Term Investments | 105.7 M |
Scandion Oncology Technical Analysis
Scandion Oncology's future price can be derived by breaking down and analyzing its technical indicators over time. Scandion Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Scandion Oncology AS. In general, you should focus on analyzing Scandion Stock price patterns and their correlations with different microeconomic environments and drivers.
Scandion Oncology Predictive Forecast Models
Scandion Oncology's time-series forecasting models is one of many Scandion Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Scandion Oncology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Scandion Oncology
Checking the ongoing alerts about Scandion Oncology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Scandion Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Scandion Oncology generated a negative expected return over the last 90 days | |
| Scandion Oncology has high historical volatility and very poor performance | |
| Scandion Oncology has some characteristics of a very speculative penny stock | |
| Scandion Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (51.7 M) with loss before overhead, payroll, taxes, and interest of (32.32 M). | |
| Scandion Oncology AS has accumulated about 131.54 M in cash with (49.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.